MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.953 MCO-0-0-953 Articles Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy YagiShigetaka 1 YahataTamaki 1 MabuchiYasushi 1 TanizakiYuko 1 KobayashiAya 1 ShiroMichihisa 1 OtaNami 1 MinamiSawako 1 TeradaMasaki 2 InoKazuhiko 1 Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan Wakayama Minami Radiology Clinic, Wakayama 641-0012, Japan Correspondence to: Professor Kazuhiko Ino, Department of Obstetrics and Gynecology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan, E-mail: kazuino@wakayama-med.ac.jp 09 2016 07 07 2016 5 3 216 222 28032016 06062016 Copyright © 2016, Spandidos Publications 2016

The objective of the present study was to investigate the prognostic value of 18F-fluoro-2-deoxy-D-glucose (FDG) uptake by primary tumors on positron emission tomography/computed tomography (PET/CT) in surgically resectable cervical cancer. A total of 59 patients with stage IA2-IIB cervical cancer who underwent preoperative FDG-PET/CT, followed by radical hysterectomy and lymphadenectomy, were included in the study. The maximum standardized uptake value (SUVmax) of the primary tumor was measured, and the association between the SUVmax and clinicopathological factors or patient outcomes was analyzed. The SUVmax was significantly higher in patients with an advanced stage, lymph node metastasis, lymph-vascular space involvement and large tumors. The overall survival (OS) and progression-free survival (PFS) of patients with a high SUVmax were significantly lower compared with patients with a low SUVmax, using an optimal cut-off value of 7.36 for OS and 5.59 for PFS obtained from receiver operating characteristic curve analysis. Similarly, OS and PFS in patients with a high SUVmax were significantly lower in 39 patients with stage IB using a cut-off value of 7.90 and 6.69 for OS and PFS, respectively. Finally, multivariate analyses showed that the SUVmax of the primary tumor was an independent prognostic factor for impaired PFS in all patients and those with stage IB alone. These findings demonstrated that a high SUVmax on preoperative PET/CT was correlated with unfavorable clinical outcomes in patients receiving radical hysterectomy, suggesting that the SUVmax of the primary tumor may be a prognostic indicator for surgically-treated, early-stage invasive cervical cancer.

 cervical cancer positron emission tomography/computed tomography maximum standardized uptake value radical hysterectomy prognosis Introduction

The second most prominent cancer in women worldwide is cervical cancer. The general treatment for cervical cancer is surgery, radiotherapy or both, with or without chemotherapy. Primary concurrent chemoradiotherapy has recently been used for advanced disease, and additionally, for early-stage locally advanced disease (1,2). In Japan, the majority of stage IB through to IIB disease patients are treated with radical hysterectomy (3,4). There is a good prognosis associated with stage IB-IIB cervical cancer; however, following surgery a significant number of patients develop recurrence. Several clinicopathological parameters have been used to assess the risk of relapse, including the histological subtype, lymph node status, lymph-vascular space involvement (LVSI), parametrial invasion and tumor size (5–8). For patients in the high-risk groups, postoperative radiotherapy with or without chemotherapy has been performed previously (3,4,9,10). However, due to its impact on survival and the quality of life, the selection of patients for adjuvant therapy remains controversial (4,9). Therefore, in addition to the conventional clinicopathological parameters, the identification of more reliable and convenient markers that are closely associated with the biological behavior of cervical cancer and the individualization of adjuvant therapy based on these indicators is required to improve the survival of patients with stage I–II disease, as well as for preventing the unnecessary use of adjuvant therapy.

The use of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) with computed tomography (CT) has been introduced over the past decade, and is now a well-established imaging modality for the diagnosis, staging and treatment monitoring of numerous types of cancer. Previous studies have shown that the maximum standardized uptake value (SUVmax), a semiquantitative simplified measurement of the tissue deoxyglucose metabolic rate measured on FDG-PET/CT, could be a parameter for evaluating malignancy and for assessing the prognosis of patients with ovarian cancer (11,12) and endometrial cancer (13–15). Therefore, the use of SUVmax as a new biomarker that is easily measureable on PET/CT prior to the start of treatment in patients with gynecological malignancies has received considerable attention.

In cervical cancer, previous studies have demonstrated the usefulness of PET/CT for the staging or assessment of lymph node metastasis (16,17). However, the correlation between the FDG uptake and clinicopathological outcome of the primary tumor has not yet been sufficiently studied and its prognostic impact remains controversial (18–21). Furthermore, there have been few studies regarding the clinical impact of the preoperative SUVmax in patients with early-stage (I–II) disease treated with radical hysterectomy (19,20,22). The present study investigated the SUVmax of primary tumors measured by preoperative FDG-PET/CT in stage IA2-IIB invasive cervical cancer patients undergoing radical hysterectomy, and aimed to clarify whether the SUVmax could be a prognostic indicator for these patients.

 Patients and methods <sec> <title>Patient selection

A total of 59 patients with stage IA2-IIB invasive cervical cancer who underwent radical hysterectomy and pelvic lymphadenectomy at Wakayama Medical University Hospital (Wakayama, Japan) between December 2008 and June 2013 were included in this retrospective study. All patients underwent preoperative FDG-PET/CT scans at Wakayama Minami Radiology Clinic subsequent to providing informed consent. No patient underwent paraaortic node biopsy/dissection as those suspected of having paraaortic node metastasis on preoperative PET/CT were excluded from the study. The median age of patients was 46 years, ranging 30–68 years. The patients were staged preoperatively according to the International Federation of Gynecology and Obstetrics (FIGO) criteria: 6 were stage IA2, 36 were IB1, 3 were IB2, 4 were IIA and 10 were IIB. The postoperative pathological diagnosis and evaluation of clinicopathological parameters, including lymph node metastasis, LVSI and tumor size, were performed by pathologists. The histological subtype was classified: 35 cases were squamous cell carcinoma (SCC), 19 were adenocarcinoma (AC) and 5 were adenosquamous carcinoma (ASC). Patients with a specific histology other than SCC and AC/ASC were not included. The FIGO stage IB patients with positive lymph nodes, LVSI or a larger tumor size (≥4 cm) and all FIGO stage II patients received postoperative adjuvant therapy involving either whole pelvic irradiation with/without chemotherapy [three courses of cisplatin (70 mg/m2) on day 1 plus 5-fluorouracil (700 mg/m2) on days 1–4; every 4 weeks] or chemotherapy alone [three courses of paclitaxel (175 mg/m2) on day 1 plus carboplatin AUC5 on day 1; every 3 weeks]. Patients receiving primary radiotherapy/concurrent chemoradiation therapy without surgery or receiving any form of preoperative treatment were excluded from this study. The study was approved by the ethics committee of Wakayama Medical University.

 FDG-PET/CT and imaging analysis

Positron emission tomography studies were performed with a PET scanner (SET-3000BCT/L; Shimadzu, Kyoto, Japan) with an axial resolution of 3.9 mm and a 20-cm field of view, as described in our previous study (12). At the time of the tracer injection, all the patients had fasted for ≥5 h and had blood glucose levels <150 mg/dl. Images were acquired from the top of the head to the mid-thigh 50 min after the intravenous injection of 18F-FDG (2.6 MBq/kg body weight). Following completion of the PET scan, CT images were obtained with a multidetector row CT scanner (Brilliance 64; Philips Medical Systems, Best, The Netherlands). Fusion images of PET and CT were made using a Workstation (EV Insite; PSP Corp., Tokyo, Japan). FDG-PET/CT images were evaluated by a nuclear medicine physician or radiologist. For each study, the SUVmax of the primary tumor was measured. SUV is a semiquantitatively analyzed value of radiotracer uptake and is defined as the ratio of radiotracer activity per milliliter of tissue to the activity in the injected dose corrected for decay and the body weight of the patient.

 Data analysis

The association between the SUVmax of the primary tumor and clinicopathological or prognostic factors was investigated. The SUVmax was compared among groups using the Mann-Whitney U test. Receiver operating characteristic (ROC) curve analysis was performed in order to determine the cut-off values of the SUVmax. Overall survival (OS) was calculated from the date of surgery to that of fatality, and progression-free survival (PFS) was calculated from the date of surgery to that of recurrence. The median follow-up period was 28.1 months, ranging 3.3–63 months. Survival analyses were performed according to the Kaplan-Meier method. A comparison of the survival between groups was performed with the log-rank test. The Cox proportional-hazard regression model was used for multivariate analyses to explore the impact of individual variables on survival. P<0.05 was was considered to indicate a statistically significant difference.

 Results <sec> <title>Association between the SUV<sub>max</sub> of the primary tumor and the clinicopathological factors

The clinicopathological characteristics and the median SUVmax of the primary tumor in each group are shown in Table I. The median of the SUVmax values for all 59 patients was 4.31, with a range of 0.00–20.29. As shown in Fig. 1A, the SUVmax for stage IB1 was significantly higher compared to that for stage IA2 (P=0.046), and the SUVmax for stage IB2 was significantly higher than those for stage IA2 and IB1 (P=0.018 and P=0.023, respectively). In addition, the SUVmax for stage IIB was significantly higher than those for stage IA2 (P=0.005) and IB1 (P=0.003); however, not for stage IB2 or IIA. Similarly, the SUVmax was significantly higher in patients with a pathologically positive pelvic lymph node (P=0.002) (Fig. 1C) and with a positive LVSI (P=0.044) (Fig. 1D), while no significant correlation was observed between the SUVmax and histological subtype (Fig. 1B). In addition, the SUVmax in patients with a pathologically measured tumor size of ≥20 mm (n=28) was significantly higher compared to in patients with a tumor size of <20 mm (n=31) (data not shown).

 Determination of cut-off values of the SUV<sub>max</sub> for predicting the presence of risk factors

As shown in Table II, ROC curve analysis demonstrated that the optimal cut-off value of the SUVmax for predicting a pathologically positive lymph node status was 6.03, with a sensitivity of 80%, specificity of 73%, and area under the curve (AUC)=0.764, while the cut-off value of the SUVmax for predicting a positive LVSI was 4.42, with a sensitivity of 67%, specificity of 63%, and AUC=0.655. There was a significant correlation between the SUVmax and lymph node status (P=0.002) or LVSI (P=0.044). Similarly, ROC curve analysis revealed that the optimal cut-off values of the SUVmax for predicting tumor sizes of ≥20 and ≥40 mm were 4.71 and 9.66, respectively, with relatively high sensitivity and specificity, and there was a significant correlation between the SUVmax and tumor size.

 Correlation of the SUV<sub>max</sub> of the primary tumor with patient survival

Based on the ROC curve analysis, the optimal cut-off values of the SUVmax for predicting OS and PFS in all 59 patients were 7.36 and 5.59, respectively (Fig. 2A and B). Using these cut-off values, the OS rate of patients with a high SUVmax (SUV ≥7.36) was significantly lower compared with patients with a low SUVmax(SUVmax<7.36) (P=0.04) (Fig. 2C). Similarly, the PFS rate of patients with a high SUVmax(SUV ≥5.59) was significantly lower compared with patients with a low SUVmax(SUVmax<5.59) (P=0.006) (Fig. 2D).

Subsequently, the impact of the preoperative SUVmax on the prognosis of 39 patients with stage IB disease alone was analyzed. Based on the ROC curve analysis, the optimal cut-off values of the SUVmax for predicting OS and PFS in stage IB patients were 7.90 and 6.69, respectively (Fig. 3A and B). The OS and PFS rates in patients with high SUVmax values (SUV ≥7.90 and ≥6.69) were significantly lower compared to those of patients with low SUVmax values (P=0.001 and P=0.014, respectively) (Fig. 3C and D).

To clarify whether the SUVmax could be an independent prognostic factor in cervical cancer patients, multivariate analyses were performed. As shown in Table III, multivariate analysis demonstrated that a high SUVmax in the primary tumor was an independent prognostic factor for impaired PFS (hazard ratio=3.947, P=0.011) among the variables including FIGO stage, lymph node metastasis, LVSI, tumor size and histological subtype. Similarly, a high SUVmax was an independent factor for predicting impaired PFS when analyzed in stage IB patients alone (hazard ratio=4.851, P=0.026) (Table IV).

 Discussion

There have been several studies showing the association between the FDG uptake within tumors evaluated by the SUVmax and clinical outcome in cervical cancer patients, although its impact on disease recurrence or survival remains controversial. Kidd et al (18) reported that the SUVmax was a sensitive biomarker of the prognosis in patients with cervical cancer including stage IA2-IVB treated with surgery, chemoradiation, or palliation. Xue et al (23) also reported that the SUVmax is predictive of the disease-free survival in stage IB1-IVB cervical cancer patients treated with radiation therapy. By contrast, Cho et al (20) demonstrated that a high pretreatment SUVmax was not predictive of recurrence in 81 patients with IB1-IVB disease treated with surgery or concurrent chemoradiation. These different results may be due to treatment bias as disease stages and treatment modalities were diverse. When focusing on surgically-treated early-stage (FIGO stage IA or IB1 to IIA) cervical cancer, there have been controversial studies on the role of the SUVmax (19,21,24). Lee et al (19) and Yun et al (24) showed that a high SUVmax was correlated with impaired disease-free survival, while Crivellaro et al (21) showed that the SUVmax was not associated with recurrence. To clarify the prognostic impact of the SUVmax on preoperative PET/CT, the present study focused on FIGO stage IA2 to IIB patients who had undergone the standardized surgical procedure (radical hysterectomy and pelvic lymphadenectomy) in a single institution.

The present results showed that a high SUVmax of the primary tumor was significantly correlated with the presence of conventional clinicopathological risk factors, such as positive lymph node metastasis, LVSI and a large tumor size. In addition, the OS and PFS in patients with a higher SUVmax were significantly lower compared with those with a lower SUVmax. Furthermore, a high SUVmax was an independent prognostic factor for impaired PFS on multivariate analysis. These findings suggest that the SUVmax of the primary tumor could be a prognostic indicator for surgically-resected early-stage invasive cervical cancer. Notably, the OS and PFS in patients with a higher SUVmax were also lower when analyzed in the stage IB group alone. As the SUVmax can be easily measured on a preoperative FDG-PET/CT, it may be a promising non-invasive biomarker to evaluate the risk of recurrence/fatality and to select patients who should receive adjuvant therapy following radical hysterectomy, particularly in stage IB patients.

In the present study, the optimal cut-off values of the SUVmax for predicting individual risk factors and assessing the prognosis using ROC curve analyses were determined. The cut-off value for predicting lymph node metastasis was 6.03. Furthermore, the cut-off levels for poor OS and PFS were 7.36 and 5.59, respectively, in all IA2-IIB patients, while those for OS and PFS in stage IB alone were 7.90 and 6.69, respectively. These values may be easy to use and aid the preoperative risk stratification in each patient as an index. Consistent with the present results, the study by Yun et al (24) showed that the cut-off value of an SUVmax >6 was predictive of disease-free survival in stage IA-IIA cervical cancer. By contrast, Lee et al (19) reported that a much higher cut-off value (SUVmax ≥13.4) was predictive of disease recurrence in stage IB1-IIA. The study by Kidd et al (18) showed three subgroups according to the SUVmax cut-off values: Low (<5.2), middle (5.2–13.3) and high risk (>13.3). The variation in the optimal cut-off values of the SUVmax among the studies may be dependent on the setting of PET scanning conditions and its imaging analysis in each institution or on the targeted patient conditions, such as disease stage.

In addition to the SUVmax, several other metabolic parameters of FDG-PET/CT have been measured in gynecological cancers. Kitajima et al (25) demonstrated that the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary tumors were correlated with clinicopathological features and are more useful for differentiating high risk from low risk compared to the SUVmax alone in endometrial cancer. In cervical cancer, their usefulness remains controversial. Kim et al (22) and Chung et al (26) reported that MTV was an independent prognostic factor for disease recurrence in patients with stage IA-IIB and IB-IIA, respectively. By contrast, the study by Crivellaro et al (21) showed that MTV and TLG were not predictors of recurrence in IB1-IIA disease. Yoo et al (27) reported that TLG and the lymph node status, but not MTV, were independent prognostic factors for survival in stage IB-IVB. Considering the importance of intratumoral FDG metabolic heterogeneity (28), the present study focusing on the SUVmax alone is simple, but may have limitations. Further studies using multimetabolic parameters of FDG-PET/CT, including the SUVmax, MTV and TLG, are required to clarify the optimal prognostic parameter for stage IA2-IIB invasive cancer patients undergoing radical hysterectomy. Furthermore, in combination with these metabolic parameters of FDG-PET analysis, immunohistochemical expression of glucose-metabolism-related proteins, such as glucose transporter 1 and cytoplasmic hexokinase II (29,30), serum SCC antigens (31,32) and the mean apparent diffusion coefficient on MRI (33) have also been reported to be prognostic biomarkers. The most appropriate combination of PET parameters with other optimal non-invasive biomarkers remains to be determined.

In conclusion, the present study demonstrated that a high SUVmax on preoperative PET/CT correlates with an unfavorable clinical outcome in FIGO stage IA2-IIB patients who have undergone radical hysterectomy. These findings suggest that the SUVmax of the primary tumor may be a promising prognostic indicator for risk stratification in surgically-treated, early-stage invasive cervical cancer patients.

 References KesicVManagement of cervical cancerEur J Surg Oncol32832837200610.1016/j.ejso.2006.03.03716698223 MonkBJTewariKSKohWJMultimodality therapy for locally advanced cervical carcinoma: State of the art and future directionsJ Clin Oncol2529522965200710.1200/JCO.2007.10.832417617527 YamagamiWAokiDAnnual report of the committee on gynecologic oncology, the Japan society of obstetrics and gynecologyJ Obstet Gynaecol Res4118611869201510.1111/jog.1283326420746 TakekumaMKasamatsuYKadoNKujiSTanakaATakahashiNAbeMHirashimaYReconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancerJ Obstet Gynaecol Res4116381643201510.1111/jog.1275426177790 TakedaNSakuragiNTakedaMOkamotoKKuwabaraMNegishiHOikawaMYamamotoRYamadaHFujimotoSMultivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomyActa Obstet Gynecol Scand8111441151200210.1034/j.1600-0412.2002.811208.x12519111 SinghNArifSHistopathologic parameters of prognosis in cervical cancer-a reviewInt J Gynecol Cancer14741750200410.1111/j.1048-891X.2004.014504.x15361180 KasamatsuTOndaTSawadaMKatoTIkedaSSasajimaYTsudaHRadical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervixBr J Cancer10014001405200910.1038/sj.bjc.660504819401699 MabuchiYYahataTKobayashiATanizakiYShiroMOtaNYagiSMinamiSInoKClinicopathologic factors of cervical adenocarcinoma stages IB to IIBInt J Gynecol Cancer2516771682201510.1097/IGC.000000000000054226495760 RosaDDMedeirosLREdelweissMIPohlmannPRSteinATAdjuvant platinum-based chemotherapy for early stage cervical cancerCochrane Database Syst Rev6CD005342201222696349 RyuHSChunMChangKHChangHJLeeJPPostoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patientsGynecol Oncol96490495200510.1016/j.ygyno.2004.10.03815661240 KitajimaKSuzukiKSendaMKitaMNakamotoYOnishiYMaedaTYoshikawaTOhnoYSugimuraKFDG-PET/CT for diagnosis of primary ovarian cancerNucl Med Commun32549553201110.1097/MNM.0b013e328345b33921407140 TanizakiYKobayashiAShiroMOtaNTakanoRMabuchiYYagiSMinamiSTeradaMInoKDiagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancerInt J Gynecol Cancer24454460201410.1097/IGC.000000000000007424463640 KitajimaKKitaMSuzukiKSendaMNakamotoYSugimuraKPrognostic significance of SUVmax (maximum standardized uptake value) measured by [18F]FDG PET/CT in endometrial cancerEur J Nucl Med Mol Imaging39840845201210.1007/s00259-011-2057-922349717 AntonsenSLLoftAFiskerRNielsenALAndersenESHøgdallETaborAJochumsenKFagö-OlsenCLAsmussenJSUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patientsGynecol Oncol129298303201310.1016/j.ygyno.2013.01.01923376805 NakamuraKHongoAKodamaJHiramatsuYThe measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancerGynecol Oncol1238287201110.1016/j.ygyno.2011.06.02621764107 GouySMoricePNarducciFUzanCGilmoreJKolesnikov-GauthierHQuerleuDHaie-MederCLeblancENodal-staging surgery for locally advanced cervical cancer in the era of PETLancet Oncol13e212e220201210.1016/S1470-2045(12)70011-622554549 KiddEASiegelBADehdashtiFRaderJSMutchDGPowellMAGrigsbyPWLymph node staging by positron emission tomography in cervical cancer: Relationship to prognosisJ Clin Oncol2821082113201010.1200/JCO.2009.25.415120308664 KiddEASiegelBADehdashtiFGrigsbyPWThe standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survivalCancer11017381744200710.1002/cncr.2297417786947 LeeYYChoiCHKimCJKangHKimTJLeeJWLeeJHBaeDSKimBGThe prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary resultsGynecol Oncol1156568200910.1016/j.ygyno.2009.06.02219604567 ChoSHLimJYKimSNHongSChungHWSoYKimWYLeeSJThe prognostic significance of pretreatment [18F]FDG-PET/CT imaging in patients with uterine cervical cancer: Preliminary resultsEur J Gynaecol Oncol363035201525872331 CrivellaroCSignorelliMGuerraLDe PontiEBudaADolciCPirovanoCToddeSFruscioRMessaC18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancerGynecol Oncol127131135201210.1016/j.ygyno.2012.06.04122772064 KimBSKimIJKimSJNamHYPakKJKimKYunMSThe prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: Measured by F-18 FDG PET/CTNucl Med Mol Imaging453642201110.1007/s13139-010-0062-824899976 XueFLinLLDehdashtiFMillerTRSiegelBAGrigsbyPWF-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapyGynecol Oncol101147151200610.1016/j.ygyno.2005.10.00516263155 YunMSKimSJPakKLeeCHAdditional prognostic value of SUVmax measured by F-18 FDG PET/CT over biological marker expressions in surgically resected cervical cancer patientsOncol Res Treat38413416201510.1159/00043895926407290 KitajimaKSuenagaYUenoYMaedaTEbinaYYamadaHOkunagaTKuboKSofueKKandaTPreoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancerEur J Nucl Med Mol Imaging4212681275201510.1007/s00259-015-3037-225833351 ChungHHKimJWHanKHEoJSKangKWParkNHSongYSChungJKKangSBPrognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancerGynecol Oncol120270274201110.1016/j.ygyno.2010.12.27021109300 YooJChoiJYMoonSHBaeDSParkSBChoeYSLeeKHKimBTPrognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomographyInt J Gynecol Cancer2212261233201210.1097/IGC.0b013e318260a90522810970 KiddEAGrigsbyPWIntratumoral metabolic heterogeneity of cervical cancerClin Cancer Res1452365241200810.1158/1078-0432.CCR-07-525218698042 TongSYLeeJMKiKDChoiYJSeolHJLeeSKHuhCYKimGYLimSJCorrelation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancerInt J Gynecol Cancer22654658201210.1097/IGC.0b013e31824864e622398711 ParkSISuhDSKimSJChoiKUYoonMSCorrelation between biological marker expression and F-fluorodeoxyglucose uptake in cervical cancer measured by positron emission tomographyOnkologie36169174201310.1159/00034994423548964 NakamuraKOkumuraYKodamaJHongoAKanazawaSHiramatsuYThe predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervixGynecol Oncol1198186201010.1016/j.ygyno.2010.04.02020580064 PanLChengJZhouMYaoZZhangYThe SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancerJ Cancer Res Clin Oncol138239246201210.1007/s00432-011-1092-z22102174 MiccòMVargasHABurgerIAKollmeierMAGoldmanDAParkKJAbu-RustumNRHricakHSalaECombined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancerEur J Radiol8311691176201410.1016/j.ejrad.2014.03.02424767630

Association between the SUVmax and clinicopathological factors in 59 cervical cancer patients. (A) Stage, (B) histology, (C) LN metastasis and (D) LVSI. SUVmax, maximum standardized uptake value; LN, lymph node; LVSI, lymph-vascular space involvement; AC, adenocarcinoma; ASC, adenosquamous carcinoma; SCC, squamous cell carcinoma; N.S., not significant.

Receiver operating characteristic curve analysis and Kaplan-Meier plots for OS and PFS in 59 cervical cancer patients. OS, overall survival; PFS, progression-free survival; SUV, standardized uptake value; AUC, area under the curve.

Receiver operating characteristic curve analysis and Kaplan-Meier plots for OS and PFS in 39 stage IB patients. OS, overall survival; PFS, progression-free survival; SUV, standardized uptake value; AUC, area under the curve.

Clinicopathological characteristics of 59 cervical cancer patients.

Characteristics Patients, n (%) Median SUVmax
Total 59 (100.0)   4.31
Stage
  IA2 6 (10.2)   1.29
  IB1 36 (61.0)   3.73
  IB2 3 (5.1) 11.03
  IIA 4 (6.8)   5.27
  IIB 10 (16.9)   8.05
Histology
  SCC 35 (59.3)   3.80
  AC/ASC 24 (40.7)   4.89
LN metastasis
  Negative 44 (74.6)   3.79
  Positive 15 (25.4)   8.56
LVSI
  Negative 35 (59.3)   3.81
  Positive 24 (40.7) 7.70

SCC, squamaous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LN, lymph node; LVSI, lymph-vascular space involvement; SUVmax, maximum standardized uptake

Receiver operating characteristic curve analyses of SUVmax cut-off values for predicting risk factors.

Variables Sensitivity, % Specificity, % AUC Optimal cut-off SUVmax value 95% CI P-value
Positive LN status 80 73 0.764 6.03 0.624–0.904 0.002
Positive LVSI 67 63 0.655 4.42 0.512–0.799 0.044
Tumor size, mm
  ≥20 71 74 0.793 4.71 0.678–0.907 <0.001
  ≥40 80 85 0.919 9.66 0.838–0.999 0.02

LN, lymph node; LVSI, lymph-vascular space involvement; AUC, area under the curve; CI, confidence interval; SUVmax, maximum standardized uptake value.

Univariate and multivariate analyses of progression-free survival in 59 cervical cancer patients.

Univariate Multivariate
Variables P-value Hazard ratio 95% CI P-value
FIGO stage
  IA2-1B2 0.026 1.429   0.431–4.740 0.560
  IIA-IIB
Histology
  SCC 0.413 0.917 0.298–2.825 0.881
  AC/ASC
LN metastasis
  Negative 0.007 1.503 0.407–5.549 0.541
  Positive
LVSI
  Negative 0.030 1.555 0.470–5.143 0.469
  Positive
Tumor size, mm
  <20 0.047 1.343 0.410–4.395 0.626
  ≥20
SUVmax
  <5.59 0.006 3.947 1.366–11.407 0.011
  ≥5.59

SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LN, lymph node; LVSI, lymph-vascular space involvement; CI, confidence interval; SUVmax, maximum standardized uptake value.

Univariate and multivariate analyses of progression-free survival in 39 stage IB patients.

Univariate Multivariate
Variables P-value Hazard ratio 95% CI P-value
Histology
  SCC 0.475 1.054 0.222–5.001 0.948
  AC/ASC
LN metastasis
  Negative 0.150 1.932 0.412–9.069 0.404
  Positive
LVSI
  Negative 0.380 1.097 0.276–4.363 0.895
  Positive
Tumor size, mm
  <20 0.134 1.171 0.216–6.352 0.854
  ≥20
SUVmax
  <6.69 0.014 4.851 1.206–19.513 0.026
  ≥6.69

SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LN, lymph node; LVSI, lymph-vascular space involvement; CI, confidence interval; SUVmax, maximum standardized uptake value.